Market Research Report
ASIA PACIFIC ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||492771|
|Published||Content info||67 Pages
Delivery time: 2-3 business days
|ASIA PACIFIC ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026|
|Published: August 6, 2018||Content info: 67 Pages||
Asia Pacific antifungal agent market is being driven by factors like poor hygiene in the region, the development of new antifungal drugs and supportive government programs. By the end of the forecast period of 2018-2026, the market is likely to register a CAGR of 5.39%.
The Antifungal agents market is segmented on the basis of type, application, therapeutic indications and drug types. Japan contributed a significant share to this market in 2017, followed by China and India.Initiatives taken by the government of these countries towards healthcare policies and programs are significantly contributing to the growth of the antifungal agents market in the Asia Pacific region. However, alternate treatment options and regulatory conditions could restrain the growth of this market in the coming years.
Companies like Abbott Laboratories, Vertex Pharmaceuticals, Bayer Healthcare, Johnson & Johnson, Baxter, Astellas Pharma Inc, GlaxoSmithKline, Novartis, Arbor Pharmaceuticals Inc, Kramer Laboratories, Pfizer, Sanofi-Aventis, Gilead and Teva Pharmaceuticals.